Post-earnings recap
Reported
Thu, Nov 14, 2019
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
75%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Aurinia Pharmaceuticals reported a loss of $0.21 per share, with no revenue figures disclosed. The stock reacted negatively, declining by 3.93%. The lack of guidance and commentary from management may have contributed to investor uncertainty.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.21 | N/A | — |
| Revenue | $— | N/A | — |
No transcript is on record for this earnings call, so the analysis is based solely on numerical results.